These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7915921)

  • 1. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease.
    Cazzola M; Santangelo G; Piccolo A; Salzillo A; Matera MG; D'Amato G; Rossi F
    Pulm Pharmacol; 1994 Apr; 7(2):103-7. PubMed ID: 7915921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
    Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
    Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
    Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
    Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ; Winter TH; Aalbers R
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
    Celik G; Kayacan O; Beder S; Durmaz G
    Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
    Lipworth BJ; Aziz I
    J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.
    Kottakis J; Cioppa GD; Creemers J; Greefhorst L; Lecler V; Pistelli R; Overend T; Till D; Rapatz Gn; Le Gros V; Bouros D; Siafakas N
    Can Respir J; 2002; 9(2):107-15. PubMed ID: 11972164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
    Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
    Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
    Brambilla C; Le Gros V; Bourdeix I;
    Clin Ther; 2003 Jul; 25(7):2022-36. PubMed ID: 12946548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients.
    Grembiale RD; Pelaia G; Naty S; Vatrella A; Tranfa CM; Marsico SA
    Pulm Pharmacol Ther; 2002; 15(5):463-6. PubMed ID: 12406669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma.
    Schermer TR; Hoff WJ; Greefhorst AP; Creemers JP; Sips AP; Westbroek J; van Herwaarden CL
    Pulm Pharmacol Ther; 2004; 17(4):205-12. PubMed ID: 15219265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).
    Benhamou D; Cuvelier A; Muir JF; Leclerc V; Le Gros V; Kottakis J; Bourdeix I
    Respir Med; 2001 Oct; 95(10):817-21. PubMed ID: 11601748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
    Condemi JJ
    Clin Ther; 2001 Sep; 23(9):1529-41. PubMed ID: 11589265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease.
    Cazzola M; Vinciguerra A; Di Perna F; Matera MG
    Respir Med; 1998 Aug; 92(8):1012-6. PubMed ID: 9893768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
    Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
    Nannini L; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.
    Grove A; Lipworth BJ
    Thorax; 1996 Jun; 51(6):585-9. PubMed ID: 8693438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.